A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging, Proof-of-concept Trial of BI 730357 Given for 12 Weeks in Patients With Active Psoriatic Arthritis
Latest Information Update: 11 Feb 2022
At a glance
- Drugs BI 730357 (Primary)
- Indications Psoriatic arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 21 Aug 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 05 Aug 2021 This trial has been Discontinued in Hungary, according to European Clinical Trials Database record.
- 29 Jul 2021 This trial has been Discontinued in Czechia, according to European Clinical Trials Database record.